This page shows the latest Remdesivir news and features for those working in and with pharma, biotech and healthcare.
The treatment – also known as remdesivir – is designed for patients who are older than 28 days, weighing at least 3kg and have either been hospitalised with COVID-19 or have the ... She added: “We need proven antiviral treatment options, like
patients. The studies, conducted by Gilead Sciences, revealed considerable insights into the use of Veklury (remdesivir) for the treatment of both hospitalised and non-hospitalised patients with COVID-19.
The benefit of baricitinib proved to be consistent regardless of which other COVID-19 treatments the patients were also receiving, including tocilizumab, corticosteroids or remdesivir.
The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that
While we continue to advance remdesivir to benefit more patients in multiple settings, we are also advancing our investigational oral compounds. ... These are based on the same antiviral mechanism of action as remdesivir and a phase 1 trial for our oral
Oral medications like molnupiravir and Paxlovid are significantly more convenient than the injectable COVID-19 treatments that are currently being used, including Gilead’s Veklury (remdesivir).
More from news
Approximately 12 fully matching, plus 42 partially matching documents found.
Trials) evaluating five-day and ten-day dosing durations of remdesivir in patients with severe disease. ... remdesivir”. Can you offer more details about the studies published in the aforementioned peer-reviewed journals?
Gilead shared some positive updates on social media about remdesivir but did not address all HCP concerns. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.
A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... Yet, it is unlikely that any of the drugs will be a panacea, with Jefferies analysts saying remdesivir “might be modestly helpful”.
An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... Lane is currently overseeing ongoing studies at the US National Institutes of
More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...